RankAlpha logo
Back to Rankings

RVMD

Revolution MedicinesB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
RVMD vs peer average
61/100
RVMD vs. peer average (B vs. C)
Grade spread
A 2 · B 2 · C 4 · D 1 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

AMGN is the first available peer comparator.

Amgen is the closest candidate in the packet for a marketed KRAS benchmark because Lumakras gives investors a real-world frame for RAS-targeted oncology commercialization, although Amgen is far more diversified and mature than RVMD.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerAMGNAmgen
RVMD
Revolution Medicines
AMGN
Amgen
Grade
B
C
Momentum
94
36
Value
41
64
Sentiment
36
47
Setup Bias
Net Bullish
-
Market Cap
-
-
Posture
Constructive
Mixed
Open Side-by-Side ComparisonCompare all

Grade position vs AMGN

RVMD / AMGN
Grade Position
In line
RVMD vs. peer average (B vs. C)
61/100
Momentum
94
RVMD
Value
41
AMGN
Sentiment
36
AMGN

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs RVMD
1
AMGN
AMGN
C
60/100
+1
2
GILD
GILD
C
60/100
+1
3
ONC
ONC
D
40/100
+2
4
ZTS
Zoetis Inc Class A Common
F
20/100
+3
5
RPRX
Royalty Pharma Plc Class A Common
B
80/100
Even
AMGN is the first peer returned for this comparison set.